When news of Melky Cabrera’s 50-game suspension for taking testosterone broke this afternoon, the Giants had 45 games remaining, were tied with the Dodgers atop the NL West, and were half a game worse than the Braves and Pirates, the two teams tentatively holding the two NL Wild Cards. Shortly after that, they lost to the Nationals, 6-4, but let’s pretend that never happened. (Who knows, maybe with Melky they would have won.) This morning, with Melky, the Giants had a 60.5 percent chance of making the playoffs: 53.2 percent from winning the division, and 7.3 percent from winning a Wild Card. How much did losing Melky for the rest of the regular season affect their odds?
To find out, I distributed Melky’s playing time among other players, re-ran the odds, and compared them to this morning’s. Our depth charts had him projected to play 90 percent of the time. I gave 60 percent of that time to Gregor Blanco (who was already projected for 40 percent) and 15 percent each to Brett Pill and Justin Christian. The difference? A whopping 2.9 percent reduction in playoff odds, with most of that decline reflected in the team’s chances of winning a Wild Card. To put that into perspective, the Giants' trade for Marco Scutaro a few weeks ago improved their playoff odds by 2.5 percent.
|
Playoff% |
Div% |
WC% |
With Melky |
60.5 |
53.2 |
7.3 |
Without Melky |
57.6 |
52.5 |
5.1 |
There is a caveat here: because it takes several years of past performance into account, PECOTA isn’t quick to believe in breakouts. As a result, the system had Cabrera projected for a .270 TAv over the rest of the season, which would have made him worth an additional half a win. However, PECOTA doesn’t know Cabrera was taking testosterone. If—and this is really a stretch—you think that either all or some portion of Cabrera’s improvement in 2012 stemmed from his use of a banned substance, then presumably he would have outperformed that projection had he continued to play, and the percentage change should be bumped up accordingly.
Even assuming Cabrera wouldn’t have regressed at all, though—which is an even bigger stretch, regardless of whether his performance was actually enhanced—his loss couldn’t have moved the needle by much more than a few percent. Forty-five games just isn’t enough time for most personnel changes to make a major impact, and it’s rare that the addition or departure of a single player makes or breaks a season. Given the closeness of the race, Cabrera’s absence could come back to bite the Giants, but unless they miss out on a playoff spot by a single game, it probably won’t be worth wondering what might have been. As demoralizing as the suspension news might be for fans of Melky or San Francisco—and for those of us who can look forward to having an even tougher time persuading people that future career years could be clean—the Giants’ playoff push isn’t in much worse shape than it was this morning.
Thank you for reading
This is a free article. If you enjoyed it, consider subscribing to Baseball Prospectus. Subscriptions support ongoing public baseball research and analysis in an increasingly proprietary environment.
Subscribe now
While we're at it, we might as well take away all the Giants victories in which Jose Guillen played in 2010. Since the Giants wouldn't have made the playoffs without those wins, we can retroactively award that World Series to the Padres. The new Padres ownership will be thrilled.
I think it's plausible that Melky's improvement was mostly some minor maturation by a player at his peak, coupled with a flukily high BABIP that probably would have regressed. Nothing about his underlying numbers really screams "steroids!" to me--most of his rates are almost identical to what they were last season, including his ISO. Of course, it's possible that he was on something in 2011, too.
This really points out the House of Cards that is PECOTA ... none of these comps mean anything for PED abusers.
Forget about what missing Cabrera means to the Giants going forward... what advantage did they accrue by having him as a cheater for the first half of the year? I'm sure the difference between his Yankee and Giant WARP is worth at least 2-3 games in the standings. That is a disservice to all of the teams chasing the Giants.
And if you really want to extrapolate .. the home field advatage for the NL in the World Series as delivered by All-Star MVP Melky.
Of course, if testosterone is as common as Conte would have us believe, we can fall back on the Apologist's list of excuses for PEDs that it really doesn't matter as it all cancels out in the end.
I think it's plausible that Melky's improvement was mostly some minor maturation by a player at his peak ... "
Sadly, entirely consistent with the BP mantra in support of PECOTA.
The comps in PECOTA are pretty worthless if you're going to use PED users to project careers of non-PED users .. or use non-PED users to project the careers of PED users.
BP has consistently underplayed the effects of PEDS because to acknowledge the effect would undermine all those PECOTA comps on which much of their analysis is based.
Just about anyone who has put up unbelievable numbers in the last 15 years has been found out to be .... well ... unbelievable.
We are on the cusp of a hall-of-fame class that should include many 1st ballot inductees but instead the players will probably never get in if the voting on Big Mac is any indication. So if you want to ignore that the best of the best of the 90s are nearly 100% indicted in the problem go ahead and bury your head in the sand.